Patents Assigned to Sollievo Pharmaceuticals, Inc
  • PARENTERAL DELIVERY OF AVIZAFONE
    Publication number: 20220225159
    Abstract: Water-stable formulations of Avizafone and methods of use are described herein. The formulations may be administered to patients intravenously, intramuscularly, or subcutaneously. For serious COVID, or other viral infections, Avizafone is a rapidly sedating benzodiazepine that could be used interchangeably with midazolam augmenting the supply of drugs for swift and intubation.
    Type: Application
    Filed: March 29, 2022
    Publication date: July 14, 2022
    Applicant: Sollievo Pharmaceuticals, Inc
    Inventor: Robert Schultz
  • PARENTERAL DELIVERY OF AVIZAFONE
    Publication number: 20220151963
    Abstract: Water-stable formulations of Avizafone and methods of use are described herein. The formulations may be administered to patients intravenously, intramuscularly, or subcutaneously. For serious COVID, or other viral infections, Avizafone is a rapidly sedating benzodiazepine that could be used interchangeably with midazolam augmenting the supply of drugs for swift and intubation.
    Type: Application
    Filed: February 1, 2022
    Publication date: May 19, 2022
    Applicant: Sollievo Pharmaceuticals, Inc
    Inventor: Robert Schultz
  • PARENTERAL DELIVERY OF AVIZAFONE
    Publication number: 20210369651
    Abstract: Water-stable formulations of Avizafone and methods of use are described herein. The formulations may be administered to patients intravenously, intramuscularly, or subcutaneously. For serious COVID, or other viral infections, Avizafone is a rapidly sedating benzodiazepine that could be used interchangeably with midazolam augmenting the supply of drugs for swift and intubation.
    Type: Application
    Filed: May 28, 2021
    Publication date: December 2, 2021
    Applicant: Sollievo Pharmaceuticals, Inc
    Inventor: Robert Schultz